Post-iodine and post-surgery management of benign thyroid disease. Narrative review and management algorithm
PDF (Español (España))
xhtml (Español (España))

Keywords

Hyperthyroidism
Disease Management
iodine
surgery

How to Cite

Mejia, M. G., Amaya Veronesi, L., & Fuentes, R. (2022). Post-iodine and post-surgery management of benign thyroid disease. Narrative review and management algorithm. Revista Colombiana De Endocrinología, Diabetes &Amp; Metabolismo, 8(3). https://doi.org/10.53853/encr.8.3.668

Abstract

Primary hyperthyroidism is a condition that requires definitive management and the antithyroid drugs are a feasible and non-invasive option, with the disadvantage of being curative only in 30% of the cases. If there is no tolerance, lack of response or side effects, definitive management with radioactive iodine or surgery is required.

Patients are frequently taken to definitive therapies, however, there is divergent evidence for follow-up after surgical or post-iodine management, and there aren`t established protocols in many institutions. Therefore, we present a review and a protocol proposal in order to homogenize the knowledge  and propound a guide for the post-therapy management of hyperthyroid patients taken to definitive treatment.

https://doi.org/10.53853/encr.8.3.668
PDF (Español (España))
xhtml (Español (España))

References

. De Leo, Lee SY, Braverman LE. Hyperthyroidism. Lancet.2016; 388: 906-18.

Taylor PN, Albrecht D, Scholz A, Gutierrez-Buey G, Lazarus JH, Dayan CM, et al. Global epidemiology of hyperthyroidism and hypothyroidism. Nat Rev Endocrinol.2018;14: 301–16.

Hollowell JG, Staehling NW, Flanders WD, Hannon WH, Gunter EW, Spencer CA, et al. Serum TSH T(4) and thyroid antibodies in the United States population: NHANES III. J. Clin. Endocrinol. Metab. 2002; 87:489–99.

Chaves W. Amador D. Tovar H. Prevalencia de la disfunción tiroidea en la población adulta mayor de consulta externa. Acta Med Colomb.2018; 43 (1): 24-30.

Klein I, Becker DV, Levey GS. Treatment of hyperthyroid disease. Ann Intern Med. 1994; 121:281–88.

Torring O, Tallstedt L, Wallin G, Lundell G, Ljunggren JG, Taube A, et al. Graves' hyperthyroidism: treatment with antithyroid drugs, surgery, or radioiodine: a prospective, randomized study. Thyroid Study Group. J Clin Endocrinol Metab. 1996;81(8):2986-93.

Boelaert K. Treatment of Graves' disease with antithyroid drugs: current perspectives. Thyroid. 2010;20:943–46.

Van Soestbergen MJ, Van der Vijver JC, Graafland AD. Recurrence of hyperthyroidism in multinodular goiter after long-term drug therapy: a comparison with Graves' disease. J Endocrinol Invest. 1992;15(11):797-800.

Franklyn JA. The management of hyperthyroidism. N Engl J Med. 1994; 330(24):1731-8.

Mumtaz M, Lin LS, Hui KC, Mohd Khir AS. Radioiodine I-131 for the therapy of graves' disease. Malays J Med Sci. 2009;16(1):25–33.

Alexander EK, Larsen PR. High dose of (131)I therapy for the treatment of hyperthyroidism caused by Graves' disease. J Clin Endocrinol Metab. 2002;87(3):1073-7.

Aljenaee K, Ali S, Cooke J, Phelan N, Pazderska N, Healy L. Early and More Frequent Monitoring of Thyroid Function Tests (TFTs) Post-RAI Could Be Clinically Beneficial. J Endocr Soc. 2019;3:592.

Tamagna EI, Levine GA, Hershman JM. Thyroid-hormone concentrations after radioiodine therapy for hyperthyroidism. J Nucl Med. 1979;20:387-91.

Kreisig T, Abenhardt W, Mann K, Kirsch CM, Moser E. Early changes in thyroid hormones following radioiodine therapy of hyperthyroidism with reference to etiology and accompanying medication. Klin Wochenschr. 1989;67(7):386-92.

Uy HL, Reasner CA, Samuels MH. Pattern of recovery of the hypothalamic-pituitary-thyroid axis following radioactive iodine therapy in patients with Graves’ disease. Am J Med. 1995; 99:173–79.

Ross D, Burch H,Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid. 2016; 26 (10): 1343-421.

Ahmad T, Khoja A, Haroon N, Ashfaq MA. Outcome of radioactive iodine therapy in Toxic Nodular Goiter in Pakistan. Pak J Med Sci. 2018; 34(5): 1146–51.

Mandel S. Larsen PR. Davies TF. (2011). Thyrotoxicosis. En: Williams. Tratado de endocrinología (pp 362-405). España: ELSEVIER.

Schäffler A. Hormone replacement after thyroid and parathyroid surgery. Dtsch Arztebl Int. 2010;107(47):827–34.

Franklyn JA. The management of hyperthyroidism. N Engl J Med. 1994;330(24):1731-8.

Shafer RB, Nuttal FQ. Thyroid crisis induced by radioactive iodine. J Nul Med.1971; 12:262-64.

Sheehan M. Doi S. Transient Hypothyroidism after Radioiodine for Graves’ Disease: Challenges in Interpreting Thyroid Function Tests, Clin Med Res. 2016; 14(1): 40–5.

Oszukowska L. Knapska M. Lewi?ski A. Effects of drugs on the efficacy of radioiodine (131|) therapy in hyperthyroid patients. Arch Med Sci. 2010; 6(1): 4–10.

Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connell J, Cooper DS, et al. Effects of antithyroid drugs on radioiodine treatment: Systematic review and meta-analysis of randomized controlled trials. BMJ. 2007;334:514.

Smith T, Hegedus L. Graves'disease. N Engl J Med. 2016.20;375(16):1552-65.

Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes K, et al. Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab. 1999;84:1229-33.

Kartamihardja AH, Massora S. The Influence of Antithyroid Drug Discontinuation to the Therapeutic Efficacy of (131)I in Hyperthyroidism. World J Nucl Med. 2016;15(2):81-4.

Mijnhout GS, Franken AAM. Antithyroid drug regimens before and after 131I-therapy for hyperthyroidism: evidence-based?. Neth J Med. 2008;66(6):238-41.

Stan MN, Durski JM, Brito JP, Bhagra S, Thapa P, Bahn RS. Cohort study on radioactive iodine-induced hypothyroidism: implications for Graves’ ophthalmopathy and optimal timing for thyroid hormone assessment. Thyroid. 2013; 23:620–25.

DeGroot LJ. Diagnosis and Treatment of Graves’ Disease. Endotext (internet). 2016. Consultado 22 Jul 2020, Disponible en: https://www.ncbi.nlm.nih.gov/books/NBK285548.

Allahabadia A, Daykin J, Sheppard MC, Gough SC, Franklyn JA. Radioiodine Treatment of Hyperthyroidism Prognostic Factors for Outcome. JCEM.2001; 86 (8): 3611–17.

Leech NJ, Dayan CM. Controversies in the management of Graves’ disease. Clin Endocrinol. 1998;49:273–80.

Wilhelm SM, McHenry CR. Total thyroidectomy is superior to subtotal thyroidectomy for management of Graves’ disease in the United States. World J Surg.2010; 34: 1261–64.

Sadler GP, Clark OH, Van Heerden JA, Farley DR. (1999). Thyroid and parathyroid. En: Schwartz Principles of surgery. (pp 1661-713). New York: McGraw-Hill.

Alsanea O, Clark O. Treatment of Graves’ disease: the advantages of surgery. Endocrinol

Metab Clin North Am 2000;29(2):321–35.

Rangaswamy M, Padhy AK, Gopinath PG, Shukla NK, Gupta K, Kapoor MM.Effect of Lugol's iodine on the vascularity of thyroid gland in hyperthyroidism. Nucl Med Commun. 1989;10(9):679-84.

Pattou F, Combemale F, Fabre S, Carnaille B, Decoulx M, Wemeau JL. Hypocalcemia following

thyroid surgery: incidence and prediction of outcome. World J Surg. 1998;22:718–24.

Lo CY, Luck JM, Sidney CT. Applicability of intraoperative parathyroid hormone assay

during thyroidectomy. Ann Surg. 2002;236(5):564–9.

Husein M, Hier MP, Al-Abdulhadi K, Black M.Predicting calcium status post thyroidectomy with early calcium levels. Otolaryngol Head Neck Surg. 2002; 127:289–93.

Bellantone R, Lombardi CP, Raffaelli M, Boscherini M, Alesina PF, De Crea C, et al. Is routine supplementation therapy (calcium and vitamin D) useful after total thyroidectomy?. Surgery. 2002; 132:1109-11.

Langley RW, Burch HB. Perioperative management of the thyrotoxic patient. Endocrinol

Metab Clin North Am. 2003;32(2):519–34.

Roos A, Linn-Rasker SP, van Domburg RT, Tijssen JP, Berghout A. et al. The starting dose of levothyroxine in primary hypothyroidism treatment: a prospective, randomized, double-blind trial. Arch Intern Med. 2005; 165:1714-20.

Boger MS, Perrier ND. Advantages and disadvantages of surgical therapy and optimal extent of thyroidectomy for the treatment of hyperthyroidism. Surg Clin North Am. 2004;84(3):849-74.

East HE. Ahmad S. Koch CA. Hormone Replacement Following Thyroidectomy. Encyclopedia of Otolaryngology, Head and Neck Surgery. Springer.2013: 1997-1202.

Boger MS, Perrier ND. Advantages and disadvantages of surgical therapy and optimal extent of thyroidectomy for the treatment of hyperthyroidism. Surg Clin North Am. 2004;84(3):849-74.

Piantanida E. Preoperative management in patients with Graves’ disease. Gland Surg. 2017; 6(5): 476–81.

Ojomo K, Schneider DF, Reiher AE, Lai N, Schaefer S, Chen H, et al. Using BMI to Predict Optimal Thyroid Dosing Following Thyroidectomy. J Am Coll Surg. 2013; 216 (3): 454-60.

Smithson M, Asban A, Miller J, Chen H. Considerations for Thyroidectomy as Treatment for Graves Disease. Clin Med Insights Endocrinol Diabetes. 2019;12: 1-5.

Lowney JK, Lairmore TC. (2002). Endocrine surgery. En: Washington manual of surgery. (pp 862-76). St Louis: Lippincott.

Xing T, Hu Y, Wang B, Zhu J. Role of oral calcium supplementation alone or with vitamin D in preventing post-thyroidectomy hypocalcaemia: A meta-analysis. Medicine.2019; 98(8): e14455.

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright (c) 2021 Revista Endocrino

Downloads

Download data is not yet available.